Close Menu

GlaxoSmithKline must have been feeling generous: the pharma gave $25 million to the Harvard Stem Cell Institute for a five-year partnership "to develop new methods for screening drugs with stem cells," according to this news item from Technology Review. "The time appears ripe for investing, because scientists can now use new reprogramming techniques to develop stem cells from patients with specific diseases."

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.